JP7072517B2 - 局所用シクロスポリン含有製剤およびその使用 - Google Patents

局所用シクロスポリン含有製剤およびその使用 Download PDF

Info

Publication number
JP7072517B2
JP7072517B2 JP2018545269A JP2018545269A JP7072517B2 JP 7072517 B2 JP7072517 B2 JP 7072517B2 JP 2018545269 A JP2018545269 A JP 2018545269A JP 2018545269 A JP2018545269 A JP 2018545269A JP 7072517 B2 JP7072517 B2 JP 7072517B2
Authority
JP
Japan
Prior art keywords
weight
hco
cyclosporine
solution
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018545269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507154A (ja
Inventor
エル． ウェイス，シドニー
ケイ． ミトラ，アシム
ジェイ． マクナリー，ユージーン
Original Assignee
サン ファーマ グローバル エフゼットイー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59744365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7072517(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サン ファーマ グローバル エフゼットイー filed Critical サン ファーマ グローバル エフゼットイー
Publication of JP2019507154A publication Critical patent/JP2019507154A/ja
Priority to JP2022077492A priority Critical patent/JP7547411B2/ja
Application granted granted Critical
Publication of JP7072517B2 publication Critical patent/JP7072517B2/ja
Priority to JP2024146154A priority patent/JP2024161602A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018545269A 2016-02-29 2017-02-28 局所用シクロスポリン含有製剤およびその使用 Active JP7072517B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022077492A JP7547411B2 (ja) 2016-02-29 2022-05-10 局所用シクロスポリン含有製剤およびその使用
JP2024146154A JP2024161602A (ja) 2016-02-29 2024-08-28 局所用シクロスポリン含有製剤およびその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662301576P 2016-02-29 2016-02-29
US62/301,576 2016-02-29
US201662302058P 2016-03-01 2016-03-01
US62/302,058 2016-03-01
US201662302730P 2016-03-02 2016-03-02
US62/302,730 2016-03-02
US201662311177P 2016-03-21 2016-03-21
US62/311,177 2016-03-21
PCT/US2017/020008 WO2017151657A1 (fr) 2016-02-29 2017-02-28 Formulations à usage topique contenant de la cyclosporine et leurs utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022077492A Division JP7547411B2 (ja) 2016-02-29 2022-05-10 局所用シクロスポリン含有製剤およびその使用

Publications (2)

Publication Number Publication Date
JP2019507154A JP2019507154A (ja) 2019-03-14
JP7072517B2 true JP7072517B2 (ja) 2022-05-20

Family

ID=59744365

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018545269A Active JP7072517B2 (ja) 2016-02-29 2017-02-28 局所用シクロスポリン含有製剤およびその使用
JP2022077492A Active JP7547411B2 (ja) 2016-02-29 2022-05-10 局所用シクロスポリン含有製剤およびその使用
JP2024146154A Pending JP2024161602A (ja) 2016-02-29 2024-08-28 局所用シクロスポリン含有製剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022077492A Active JP7547411B2 (ja) 2016-02-29 2022-05-10 局所用シクロスポリン含有製剤およびその使用
JP2024146154A Pending JP2024161602A (ja) 2016-02-29 2024-08-28 局所用シクロスポリン含有製剤およびその使用

Country Status (21)

Country Link
US (4) US10918694B2 (fr)
EP (2) EP3423076B1 (fr)
JP (3) JP7072517B2 (fr)
KR (1) KR102766771B1 (fr)
CN (2) CN109843316A (fr)
AU (2) AU2017227585C1 (fr)
BR (1) BR112018067946A8 (fr)
CA (1) CA3015626A1 (fr)
DK (1) DK3423076T3 (fr)
ES (1) ES2981702T3 (fr)
FI (1) FI3423076T3 (fr)
IL (1) IL268056A (fr)
MX (2) MX2018010395A (fr)
NZ (2) NZ785158A (fr)
PL (1) PL3423076T3 (fr)
PT (1) PT3423076T (fr)
RU (1) RU2747455C2 (fr)
SA (1) SA519410114B1 (fr)
SG (1) SG11201906729RA (fr)
WO (1) WO2017151657A1 (fr)
ZA (1) ZA201904704B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1211867A1 (en) 2012-08-24 2016-06-03 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
WO2017083167A1 (fr) 2015-11-10 2017-05-18 Ocular Technologies Sarl Formulations topiques et utilisations associées
RU2747455C2 (ru) 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
CN112957450A (zh) * 2019-12-20 2021-06-15 艾棣维欣(苏州)生物制药有限公司 一种难溶性药物的水溶液及其制备方法
JP2024521968A (ja) 2021-06-14 2024-06-04 サン ファーマシューティカル インダストリーズ リミテッド 白内障手術を受ける患者において使用するための、シクロスポリン製剤
MX2024002234A (es) * 2021-08-20 2024-04-17 Sun Pharmaceutical Ind Ltd Formulación oftalmológica de ciclosporina estable y proceso de fabricación de esta.
WO2024042550A1 (fr) * 2022-08-25 2024-02-29 Sentiss Pharma Private Limited Composition de combinaison ophtalmique
IL320428A (en) 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
EP4719350A1 (fr) 2023-05-29 2026-04-08 Sun Pharmaceutical Industries Limited Formulation ophtalmique de cyclosporine stable et son procédé de fabrication

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057854A1 (en) 2012-08-24 2014-02-27 Ashim K. Mitra Topical formulations and uses thereof
WO2015179527A1 (fr) 2014-05-23 2015-11-26 Ocular Technologies Sarl Formulations topiques et leurs utilisations
JP2018532809A (ja) 2015-11-10 2018-11-08 サン ファーマ グローバル エフジーイー 局所製剤およびその使用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1004520A1 (en) 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
IL160761A0 (en) 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
WO2004069181A2 (fr) 2003-02-03 2004-08-19 Pharmacia Corporation Compositions d'un agent modulateur de l'aquaporine et d'un agent modulateur de l'humeur aqueuse pour le traitement d'une pression intra-oculaire elevee
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004096261A1 (fr) 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Procede de preparation d'une solution aqueuse de cyclosporine-a et solution aqueuse ainsi obtenue
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
EP1889620A4 (fr) 2005-06-09 2008-12-10 Santen Pharmaceutical Co Ltd Gouttes oculaires contenant du roflumilast
EP1890677A4 (fr) 2005-06-16 2013-01-30 Myriad Genetics Inc Compositions pharmaceutiques et leur utilisation
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
EP1904056B1 (fr) 2005-07-18 2009-04-29 Minu, L.L.C. Utilisation d'un macrolide pour restaurer la sensation cornéenne
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US20090074874A1 (en) 2006-04-24 2009-03-19 Yuko Amano Process for Producing Polymer Micelles Encapsulating Low Molecular Weight Drugs
WO2007136134A1 (fr) 2006-05-23 2007-11-29 Nanocarrier Co., Ltd. Procédé de production de micelles polymères destinées à contenir un médicament hydrophobe
KR101363498B1 (ko) 2006-07-18 2014-02-14 나노캬리아 가부시키가이샤 생리활성 폴리펩티드 또는 단백질 내포 고분자 폴리머 미셀및 그 제조방법
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
PT2193795E (pt) 2007-08-29 2014-10-22 Wakamoto Pharma Co Ltd Composição farmacêutica aquosa contendo latanoprost
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
US20090286718A1 (en) 2008-01-04 2009-11-19 Sirion Therapeutics, Inc. Stable Aqueous Cyclosporin Compositions
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
US20090298956A1 (en) 2008-05-28 2009-12-03 Chowhan Masood A Self-preserved emulsions
EP2127638A1 (fr) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Procédé et composition pour traiter l'hypertension oculaire et le glaucome
BRPI1010175A2 (pt) 2009-06-02 2016-03-29 Keller Brian Charles "composição química que inclui um conjugado de lipídio-peg e lipossoma"
EP2440185B1 (fr) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Systemes d'administration de medicament topique pour une utilisation ophtalmique
WO2011034192A1 (fr) 2009-09-17 2011-03-24 千寿製薬株式会社 Gouttes ophtalmiques aqueuses qui contiennent du latanoprost, et procédé d'inhibition de l'adsorption du latanoprost sur une résine
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011106697A1 (fr) 2010-02-25 2011-09-01 Schepens Eye Research Institute Compositions thérapeutiques pour le traitement de la maladie de l'œil sec
US20130267591A1 (en) 2010-05-07 2013-10-10 Sun Pharma Advanced Research Company Limited Novel ophthalmic compositions
WO2013025696A1 (fr) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Formulations ophtalmiques et leurs procédés de préparation
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
KR101211902B1 (ko) * 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
CA2872958A1 (fr) 2012-05-11 2013-11-14 Cipla Limited Composition pharmaceutique
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016178881A1 (fr) 2015-05-04 2016-11-10 Ocular Technologies Sarl Formulations topiques et utilisations de celles-ci
WO2017083410A1 (fr) 2015-11-12 2017-05-18 Ocular Technologies Sarl Formulations topiques et leurs utilisations
RU2747455C2 (ru) 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
WO2017152129A2 (fr) 2016-03-03 2017-09-08 Ocular Technologies Sarl Traitement du glaucome et/ou de maladies rétiniennes, et formulations utiles pour ce traitement
JP2024521968A (ja) * 2021-06-14 2024-06-04 サン ファーマシューティカル インダストリーズ リミテッド 白内障手術を受ける患者において使用するための、シクロスポリン製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057854A1 (en) 2012-08-24 2014-02-27 Ashim K. Mitra Topical formulations and uses thereof
WO2015179527A1 (fr) 2014-05-23 2015-11-26 Ocular Technologies Sarl Formulations topiques et leurs utilisations
JP2018532809A (ja) 2015-11-10 2018-11-08 サン ファーマ グローバル エフジーイー 局所製剤およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｎｅｗｓ Ｒｅｌｅａｓｅ，Ａｕｖｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，2015年11月13日，http://www.auventx.com/auven/news/2015.php

Also Published As

Publication number Publication date
SG11201906729RA (en) 2019-08-27
PT3423076T (pt) 2024-07-01
RU2747455C2 (ru) 2021-05-05
JP2024161602A (ja) 2024-11-19
US20190060397A1 (en) 2019-02-28
US10918694B2 (en) 2021-02-16
AU2022203135A1 (en) 2022-06-02
JP2019507154A (ja) 2019-03-14
EP4410312A2 (fr) 2024-08-07
US11951153B2 (en) 2024-04-09
CA3015626A1 (fr) 2017-09-08
AU2022203135B2 (en) 2025-09-11
NZ785158A (en) 2025-03-28
IL268056A (en) 2019-08-29
BR112018067946A8 (pt) 2022-11-08
CN119185511A (zh) 2024-12-27
US20240197818A1 (en) 2024-06-20
JP7547411B2 (ja) 2024-09-09
US20210145924A1 (en) 2021-05-20
KR20180117661A (ko) 2018-10-29
NZ755442A (en) 2023-04-28
WO2017151657A1 (fr) 2017-09-08
EP3423076A4 (fr) 2019-11-27
BR112018067946A2 (pt) 2019-01-15
EP4410312A3 (fr) 2024-11-20
FI3423076T3 (fi) 2024-06-24
KR102766771B1 (ko) 2025-02-14
EP3423076A1 (fr) 2019-01-09
AU2017227585C1 (en) 2022-05-26
DK3423076T3 (da) 2024-07-08
PL3423076T3 (pl) 2024-08-19
EP3423076B1 (fr) 2024-04-17
US20230083458A1 (en) 2023-03-16
MX2018010395A (es) 2018-11-29
SA519410114B1 (ar) 2024-02-11
CN109843316A (zh) 2019-06-04
MX2024010721A (es) 2024-09-10
RU2019130403A (ru) 2021-03-26
ZA201904704B (en) 2022-10-26
ES2981702T3 (es) 2024-10-10
RU2019130403A3 (fr) 2021-03-26
AU2017227585A1 (en) 2018-10-18
JP2022110054A (ja) 2022-07-28
AU2017227585B2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP7547411B2 (ja) 局所用シクロスポリン含有製剤およびその使用
US9937225B2 (en) Topical formulations and uses thereof
JP5668476B2 (ja) カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
HK40114670A (en) Topical cyclosporine-containing formulations and uses thereof
HK40002770B (en) Topical cyclosporine-containing formulations and uses thereof
HK40002770A (en) Topical cyclosporine-containing formulations and uses thereof
OA19679A (en) Topical cyclosporine-containing formulations and uses thereof.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200227

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20200925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210402

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210817

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210903

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220510

R150 Certificate of patent or registration of utility model

Ref document number: 7072517

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250